Clinical evidence: DBS for severe substance-use disorder

For healthcare professionals

Clinical evidence: DBS for severe substance-use disorder

The supplied clinical materials describe research in carefully selected cohorts with severe, treatment-resistant substance-use disorder. Reported assessments span biological testing, craving, mood, cognition, personality and social functioning.

Key point

The reports describe sustained abstinence-related findings and reduced craving in their study cohorts. These are program-specific observations, not a basis for individual prognosis or blanket comparative-effectiveness claims.

Clinical perspective

Interpretation should account for study design, sample size, retention, endpoint definition, concomitant care and external validity.

More context

The clinical materials supplied for this site describe outcomes within specific programs and cohorts. Such reports are valuable for hypothesis generation and service development, but they should be read alongside study methods, patient characteristics, concurrent care, missing data and outcome definitions. A sustained result in a reported cohort is not equivalent to a guaranteed outcome for an individual patient.

What to cover with a specialist team

A robust multidisciplinary review asks not only whether symptoms might improve, but also whether the person can safely participate in the full care pathway. This includes capacity and consent, psychiatric stability, substance-use risk, medical and surgical risk, ability to attend follow-up, psychosocial support and a plan for managing adverse events or changing clinical needs.

Practical preparation

  • State the evidence level and uncertainty clearly when discussing options.
  • Document baseline substance use, psychiatric symptoms, cognition and social functioning.
  • Define monitoring intervals and escalation pathways before treatment begins.
  • Review benefit, harm, adherence and patient-reported outcomes longitudinally.

Limits and safety

This article supports informed conversation; it cannot diagnose an individual or replace clinical advice. Suitability for any intervention must be determined by the responsible medical team after comprehensive assessment.

Source: Clinical Efficacy and Safety materials (2025) and White Paper (2026). Educational summary only; no product or commercial material is included.

Scroll to Top